Elazığ Mental Health and Diseases Hospital
11
4
4
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis
Role: lead
Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use
Role: lead
ECG Findings in Methamphetamine Use
Role: lead
Cognitive Disengagement Syndrome in Functional Neurological Symptom Disorder
Role: lead
LRFN5 and OLFM4 in Schizoaffective Disorder
Role: lead
IL-33, sST2, and CRP in Panic Disorder
Role: lead
LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
Role: lead
α-N-acetylgalactosaminidase in Methamphetamine Psychosis
Role: lead
LRFN5 and OLFM4 in Schizophrenia
Role: lead
LRFN5 and OLFM4 in Bipolar Disorder
Role: lead
α-N-acetylgalactosaminidase Levels in Panic Disorder
Role: lead
All 11 trials loaded